Abstract: Human diseases such as cancer can be caused by aberrant epigenetic regulation. Polyphenols play a major role in mammalian epigenome regulation through mechanisms and proteins that remodel chromatin. In fruits, seeds, and vegetables, as well as food supplements, polyphenols are found. Compounds such as these ones are powerful anticancer agents and antioxidants. Gallic acid, kaempferol, curcumin, quercetin, and resveratrol, among others, have potent anti-tumor effects by helping reverse epigenetic changes associated with oncogene activation and tumor suppressor gene inactivation. The role dietary polyphenols plays in restoring epigenetic alterations in cancer cells with a particular focus on DNA methylation and histone modifications was summarized. We also discussed how these natural compounds modulate gene expression at the epigenetic level and described their molecular targets in cancer. It highlights the potential of polyphenols as an alternative therapeutic approach in cancer since they modulate epigenetic activity.

Keywords: cancer; polyphenol; epigenetics

1. Introduction

Epigenetics is the study of how genes and their products affect an organism’s phenotype [1]. Since the discovery of DNA, epigenetics has not received much attention. In the 1980s, however, studies of chromatin structure made epigenetics respectable after being shrouded in the shadows [2]. In 1987, Robin Holliday redefined epigenetics as nuclear inheritance without DNA sequence differences [3]. It offers possible explanations for cellular differentiation and parental imprinting in mammals, and it enables genetics and developmental embryology to be integrated [4]. Furthermore, epigenetic modifications play a crucial role in developmental patterning, biological processes, and pathology [5–7]. In mammalian cells, DNA methylation and histone modifications induce chromatin remodeling, leading to cellular phenotype changes [8–11]. Diverse epigenetic changes occur in cancer cells in the early stages of tumor development [12]. These epigenetic modifications of chromatin are inherited and reversible, so they could be used to develop drugs targeting the epigenome which could help treat cancer [13–15]. The use of new therapeutic drugs and personalized treatment leads to improved patient survival. Dietary supplements have been combined with some of these treatments [16–18]. Diets high in vegetables and fruits have been proven to reduce the risk of cancer. This is because they regulate the expression of oncogenes and tumor suppressor genes [19]. Dietary supplements might be an alternative cancer treatment. In this study, we provide an overview of the most common epigenetic alterations seen in cancer, then discuss the most studied dietary patterns and how they...
might be used to reverse epigenetic changes, and lastly, discuss how they might be used as an alternative therapy for cancer.

2. Oxidative DNA Damage and Polyphenols

Polyphenols have antioxidant properties which as a therapeutic action against cancer. It is found that polyphenol has a dominant antioxidant that mitigates oxidative stress from pathological conditions such as cancer. Polyphenol can scavenge ROS and act on free radicals. This is due to the presence of aromatic rings, the presence of hydroxyl groups in a different region, and has more conjugated system [20]. Polyphenol scavenges Reactive Oxygen Species (ROS) and mitigates the biomolecule oxidative damage [21,22]. Polyphenols with antioxidant capacity suppress the signaling pathways involved in oxidative stress generation at a molecular level. Consumption of a polyphenol diet increases the activity of the antioxidant and inhibits the peroxidation of lipids and cyclooxygenase (COX) pathways [23]. Increased levels of free radical production such as ROS and LPO with oxidative stress cause damage to the tissues inclusive of DNA and increases the possibility of cancer occurrence. Increased ROS level is due to exogenous, antioxidant defense, and endogenous sources. The exogenous sources include X-rays, UV light irradiation, the action of metals, toxins, and γ rays, drugs, and solvents; endogenous sources include peroxisomes, metabolism of cytochrome P450; reactions in mitochondria; and activation of inflammation. This exogenous and endogenous source of ROS is important for oxidative stress-mediated ROS production causes damage to the cell, and alters the signaling pathway, which further causes cancer [24]. Damages to the DNA can cause errors in the replication, arresting transcriptional activities, instability of the DNA damage, and further causes cancer [25,26]. Different studies show a reduction in endogenous DNA damage and protection from ex vivo DNA damage [27]. A diet such as vegetables and fruits has a high content of polyphenols which includes quercetin, ellagic acid, catechins, naringenin, and resveratrol. This polyphenol can decrease the risk of cancer. Polyphenols have a chemopreventive action which includes the involvement of antiestrogenic, arresting cell cycle, proliferation against cancer cells, resistance to the oxidative stress, induction of apoptosis, detoxification enzyme activation, regulation of the host immune system, and cellular signaling improvement in the cancer condition [28]. Polyphenols show protection from cancer when combined with DNA-damaging agents. Polyphenols impair the metabolism of pro-carcinogen by altering the level of enzyme cytochrome P450 which plays an important role in the stimulation of cancer [29]. Polyphenol and quercetin have properties of anti-cancer action by reducing free radical-ROS scavenging activity [30]. The polyphenols present in black tea such as theaflavins, EGCG, and thearubigins have effective properties of anti-cancer [31–33]. The catechins present in the tea can prevent cancer by impairing intraepithelial prostate lesions converting them into cancer and decreasing the cancer cell apoptosis, thereby it inhibits carcinogenesis [34]. The flavonoids like catechins, anthocyanins, flavanols, flavanones, flavones, and isoflavones, have a capacity for free radicals neutralization via scavenging ROS and impairs the risk of cancer by cellular growth arrest in cancer cells [35]. There are different types of cancer such as prostate, endometrial, epithelial, breast cancer and colon cancer are mitigated by polyphenols [36]. Resveratrol has an anti-cancer property via an antioxidant defense mechanism which impairs the hydroperoxidase level, matrix metalloproteinase level (MMP-9), Akt signaling pathway, NF-KB pathway, cyclooxygenase pathway, protein kinase C, Bcl-2 level and focal adhesion kinase [37].

3. Human Cancer and DNA Methylation

In cancer, epigenetic changes include genome-scale methylation changes, hypermethylation in specific loci, and dysfunction of histone-modifying enzymes. Changes in DNA methylation are good biomarkers since they can be detected and quantified [23,38,39]. Many studies have found DNA methylation patterns specific to liver cancers, including genome-wide studies [40–45]. According to DNA methylation and transcriptome mapping in human tumors, a lot of genes are hypomethylated and expressed more, and a lot of genes
are hypermethylated and underexpressed. The genes induced by epigenetics were found to be involved in cellular transformation and differentiation, tumor growth, and metastasis. Apoptosis, cell adhesion, and cell cycle progression genes are repressed [46–48]. Even though genome-wide DNA methylation studies are a hot topic, there are a few caveats that urge caution about the clinical and biological significance of the data [49]. Most importantly, tumors have a lot of cellular heterogeneity, so observed differences in DNA methylation patterns might just be due to differences in tumor cell numbers, rather than being an epigenetic signature. The DNA methylation profiling needs to be performed on small numbers of histologically verified tumor cells sorted by high-speed cell sorting or laser dissection microscopy. Another caveat is that we shouldn’t assume a simple relationship between DNA methylation and gene expression, even if transcriptome data indicates that. In vivo experiments would need to manipulate DNA methylation site-directedly and demonstrate transcription rate changes (Table 1).

| Polyphenols       | Molecular Mechanism | Pre Clinical Model | Target Gene |
|-------------------|---------------------|--------------------|-------------|
| Curcumin          | DNMT inhibitor      | Leukemia, esophageal | NA          |
| Epicatechin,      | DNMT inhibitor      | Lung, colon cancer cells, esophageal, oral, breast cancers | RAÎ, MGMT, MLH1, CDKN2A, RECK, TERT, RXR, CDX2, GSTP1, W1F1 |
| epicatechin-3-     | DNMT inhibitor      | Breast, colon, esophageal cancers | CDKN2A      |
| epigallocatechin-3-| DNMT inhibitor      | Breast, Lungs cancers | NA          |
| gallocate          | DNMT inhibitor      | Histone modifications | GATA4, EOMES, GZMB, PRF1, H3/H4 deacetylation |
| Resveratrol        | DNMT inhibitor      | anti-inflamatory, anticancer, antioxidant, antiproliferative | NF-kB, IL-6, BMI-1, EZH2, SUZ12, H3K27 trimethylation, H3/H4 acetylation |
| Curcumin           | HAT and HDAC inhibitor | antioxidant, anticancer, anti-inflammatory | Inflammatory diseases |
| Epicatechin,       | HAT inhibitor       | anti-migration, anticancer, antiproliferative, antidiabetic, antioxidant | TNF-α, IL-8, RBP |
| epicatechin-3-     | HAT inhibitor       | Breast, colon, esophageal cancers | CDKN2A      |
| epigallocatechin-3-| HAT inhibitor       | Breast, Lungs cancers | NA          |
| gallocate          | HAT inhibitor       | anti-inflamatory, anticancer, antiproliferative, antidiabetic, antioxidant | TNF-α, IL-8, RBP |

4. Cancer and Histones

DNA is packed into chromatin around an octamer of histones in a chromosome. A nucleosome is a repeating unit of chromatin that is made up of 150 base pairs of DNA and an octamer of histones, H2A, H2B, H3, and H4 [49–52]. Histone tails are targets for post-translational modifications, including acetylation, methylation, phosphorylation, and ubiquitination [53,54]. DNA modifications can turn the transcription of genes on or off,
which affects the accessibility of transcription factors by adjusting how tightly DNA is bound to histones. HATs, which “write” the acetyl mark on histones, are responsible for histone acetylation. By counteracting the positive charge of histones, it loosens the connection between histones and DNA. In contrast, histone deacetylases (HDACs) “erase” those acetyl groups, resulting in tight DNA coiling around the histones, making chromatin transcriptionally inactive. Histone methylation is associated with either transcriptionally active or closed chromatin depending on where the lysine is methylated [55]. The trimethylation of histone 3 lysine 27 (H3K27me3), for example, is associated with transcriptional repression, whereas trimethylation of histone 3 lysine 4 is associated with gene activation [56,57]. Cancer patients with high levels of trimethylated histone H3 lysine 4 (H3K4me3) have a poor prognosis. H3K27me3 levels were linked to poor prognosis and tumor aggressive features including vascular invasion, large tumor sizes, multiple tumors, and poor differentiation in another study [56,58,59]. To fully understand the role of these specific DNA-protein modifications in cancer, further studies using more precise detection methods, such as ChIP-sequencing, will be needed.

5. Inhibitors of DNA Methylation

The epigenome is reprogrammed as soon as embryogenesis begins because DNA methylation decreases. Methylation of DNA requires methylating enzymes, so cellular replication without these enzymes leads to significant demethylation of daughter cells and gene reactivation. This approach has a therapeutic ratio when applied to cancer cells; normal cells usually survive hypomethylation, whereas cancer cells usually die when it occurs, perhaps because they are dependent on gene silencing.

DNA hypomethylation only happens with cytosine analogs with 5′ modifications of the ring. Nucleoside and cytosine analogs do not directly affect DNA methylation. It was determined that the ability of these two main analogs to target DNA methyltransferases (DNMTs) for degradation was attributed to their ability to trap DNA methyltransferases (Table 1). In the absence of these enzymes, DNA synthesis results in hypomethylation in daughter cells, which in turn leads to the reactivation of silenced genes. Some other 5′ modified nucleoside analogs have been described in preclinical or early clinical studies [60]. Inhibiting DNA methylation in cancers works, at least in part, by inhibiting DNA methylation.

6. Inhibitors of Histone Modification

Inhibitors of histone deacetylase (HDACi) decrease HDAC activity, block acetylated histone aggregation, and promote autosomal acetylation. HDACi promotes cancer cell differentiation, induces apoptosis, and inhibits angiogenesis through many mechanisms, including cell cycle arrest, apoptosis, autophagy, and differentiation. HDACi are classified into four classes based on their chemical. In addition to in vitro and in vivo studies, hydroxamates and aliphatic acids have also been tested in clinical trials as a new treatment strategy for hepatobiliary cancer [61–64]. Panobinostat, trichostatin A, vorinostat, and belinostat are hydroxamates that block HDAC activity by binding to Zn\(^{2+}\) at the HDAC binding site. Besides aliphatic acids, sodium butyrate and valproic acid (VPA) inhibit class I HDACs as well [65,66]. For example, this occurs with VPA, sodium butyrate, and TSA. By downregulating cyclins A and D1 and upregulating P21, VPA could induce cell cycle arrest [67]. Additionally, sodium butyrate upregulated p21 and p27 protein expression [68–70]. Furthermore, TSA causes G2/M-phase arrest and G0/G1 arrest in hepatoma cells [71,72]. The fact that apoptosis plays an important role in tumor development makes it an obvious target for cancer therapy. HDACi promotes apoptosis in cancer cells. In addition, HDACi promotes apoptosis by different mechanisms; for example, VPA activates TRAIL-associated cell death and intrinsic apoptosis by upregulating cleaved caspases 3 and 9 [73]. Specifically, TSA upregulates bax and cleaved caspase 3 and downregulates BCL-2 in cancer cells [74,75]. Further, it has been found that HDACi can induce autophagy-mediated cell death, and cancer cell lines showed autophagosome formation, maturation, and aggregation when
exposed to panobinostat. Several inhibitors of angiogenesis have been found to interact with HDACi in a synergistic way to inhibit hepatobiliary cancers [76,77]. Some clinical trials have tested HDACi’s anticancer effects, especially when combined with sorafenib.

7. Polyphenol and Cancer

There is usually at least one hydroxyl group attached to an aromatic ring in these compounds. Polyphenolic molecules have been found in thousands of higher plants and hundreds of edible plants [78,79]. There are two types of polyphenols in plants: flavonoids and non-flavonoids [80]. Flavanoids share 15 carbon atoms at their core and are divided into flavanols, flavonols, anthocyanidins, flavones, flavanones, and chalcones [81]. The non-flavonoids contain an aromatic ring with one or more hydroxyl groups. Stilbene, phenolic acids, saponin, and other polyphenols such as curcumin and tannins are not flavonoids. Plants synthesize polyphenols to defend themselves against infection and protect themselves from stress. In recent years, plant polyphenols have received substantial attention for their cancer-preventing effects. Several studies have demonstrated that plant polyphenols are chemopreventive against multiple types of cancer [82–87].

7.1. Epigenetics Mechanism of Kaempferol

The natural flavonoid kaempferol (KFL) is widely found in fruit and veggies. Many cancers, such as breast cancer, pancreatic cancer, prostate cancer, and lung cancer, have been reported as being susceptible to KFL [88–91]. A previous study has shown that KFL could affect DNA methylation in nude mice treated with bladder cancer [92]. In their experiments, they found that KFL inhibited the levels of DNMT3B protein without affecting DNMT1 and also found that cycloheximide inhibited protein synthesis of DNMT3B and caused DNMT3B to prematurely degrade and block proteasome with MG132, causing KFL to ubiquitinate DNMT3B. Results suggest that KFL can degrade DNMT3B through the ubiquitin-proteasome pathway [93]. Another study showed treatment with KFL increased DACT2 in three colorectal cancer cells. In addition, KFL reduced DACT2 methylation but increased unmethylated DACT2 by binding directly to DNA methyltransferases DNMT1 [93]. Kaempferol epigenetically reactivates DACT2 transcription to inhibit nuclear β-catenin expression, which in turn inhibits Wnt/β-catenin signaling, which restricts CRC cell proliferation and migration. Additionally, kaempferol-demethylated DACT2 reduced tumor load in AOM/DSS-induced CRC tumorigenesis. Tae et al. found that kaempferol activates autophagy via the inhibition of G9a [94]. According to this study, kaempferol activates IRE1-JNK-CHOP signaling from the cytosol to the nucleus and inhibiting G9a triggers autophagy [95–101] (Figure 1).

7.2. Epigenetic Mechanism of Gallic Acid

Among the emerging cancer treatments is gallic acid (GA) [102–104]. Studies have shown it suppresses hepatic cancer cell viability, proliferation, invasion, and angiogenesis [105–108]. In addition to being an antioxidant, GA is also a pro-oxidant. In H1299 cells, GA reactivates the growth arrest and DNA damage-inducible 45 (GADD45) signaling pathway through demethylation of CCNE2 and CCNB1 [109]. Through a two-week fermentation process, Aspergillus sojae is able to efficiently increase the GA content in oolong tea, improving the epigenetic anticancer properties of GA. DNMT1, DNMT3A, and DNMT3B in human cancer cell lines were significantly reduced when the fungus dramatically increased GA up to 45 fold [110]. As a result, fermented oolong tea high in GA appears to be an effective dietary intervention strategy for tobacco-associated cancers because of its potent inhibitory effects on DNMTs. As confirmed by histological analysis, oral administration of GA for 8 weeks decreases tumor size, damages tumor structure, and lowers expression of HDAC1 and PCNA in tumor mass [111]. As an HDAC inhibitor and anti-PCa therapy, GA may inhibit PCa progression by inhibiting HDAC1 and two expressions.
Gallic acid from Rosa rugosa inhibited the majority of histone acetyltransferases (HATs) in another study [112]. Including sirtuin, histone deacetylase, and histone methyltransferase. Gallic acid inhibits p300/CREBBP-dependent HAT activities uncompetitively. Both in vitro and in vivo, GA inhibits p300-induced p65 acetylation. It prevents the nuclear translocation of p65 caused by lipopolysaccharide (LPS). It suppresses LPS-induced nuclear factor-κB activation in A549 lung cancer cells [113] (Figure 2) [110–112].

Figure 1. Molecular mechanism represents the role of kaempferol in epigenetic modulation during cancer and how it protects from cancer. Kaempferol protecting against cancer via a different mechanism such as inhibition of DNMT3B which prematurely degrades and blocks proteasome with MGI32 further causes autophagy via G9a inhibition and ubiquitin-mediated proteolysis; on the other hand, reactivated DACT2 inhibits Wnt-β-catenin signaling pathway and leads to impairment of the CRC cell proliferation and migration further causes epigenetic modulation and protects against cancer; increased localization of the IRE-JNK CHOP from cytosolic to the nucleus further inhibits G9a; decreased DACT2 methylation; increased unmethylated DACT2 binds directly to DNA methyltransferase DNMT1 and is involved in epigenetic modulation during cancer.
7.3. Epigenetic Modulation of Curcumin in Cancer

Curcumin modulates HDAC or HAT activity in a variety of in vitro cancer cell models [114–116]. Curcumin inhibits Notch-1 and the pro-inflammatory nuclear transcription factor-kappa B by inhibiting p300-mediated acetylation of its RelA isoform [117]. The researchers showed that curcumin reduces HAT activity in human acute monocytic leukemia THP-1 cells by hypoacetylation p65 at Lys310 and preventing nuclear transcription factor kappaB activity [118]. It has been shown that curcumin induces histone hypoacetylation in brain glioma cells, which results in subsequent apoptotic cell death through PARP- and caspase-3-mediated mechanisms [106]. Recent studies have shown curcumin acts as an epigenetic modulator of TREM-1 gene expression by inhibiting p300 activity in the TREM-1 promoter region, causing hypoacetylation of histones 3 and 4 [118].

During prostate cancer progression in TRAMP mice, Nrf2, the master regulator of cellular antioxidant defenses is epigenetically silenced. Furthermore, curcumin induces hypomethylation of Fanconi anemia (FANCF) promoter that leads to an increase in FANCF protein and gene expression in SiHa cells and a subsequent reduction in ovarian tumor cell proliferation [119]. In MV4-11 leukemia cells, curcumin induces global hypomethylation [120]. Based on molecular docking, curcumin covalently binds to the catalytic thiolate of DNMT1 with an IC50 of 30 nM treatment, causing DNA methylation to be inhibited. More recently, in vitro methylation assays showed that M.SsSl, a DNMT1 analog, was inhibited by 50 µM of curcumin in SiHa ovarian cancer cells [108]. This epigenetic event may be related to NF-κB/Sp1 disrupting DNMT1’s promoter. Another study showed that at 5 µM concentration, curcumin also reversed CpG methylation in Neurog1, a cancer methylation marker known to be highly methylated and whose expression is disrupted in human prostate cancer cells [121]. Therefore, curcumin could be a DNMT inhibitor.

Figure 2. Gallic acid protects from cancer. Gallic acid suppresses cell viability, proliferation, invasion, and angiogenesis; reactivates growth arrest and GADD45; increases demethylation and increases the DNMT1, DNMT3A, and DNMT3B found to be more in the nucleus; decreases HDAC1 and 2; increases acetyl-p53; decreases PCNA; cyclin D and E; up-regulation of p21, decreases BAX, Cas3, and PARP, and increases Bcl2; inhibits P300/CBP-dependent HAT activation; P300-p65 inhibition; cytosolic IKBα; inhibition of NF-kB; and further protects from cancer.
Using a 2.5 μM dose of curcumin can also restore Nrf2 expression via promoter CpGs demethylation in TRAMP C1 prostate cancer cells [122]. The p300/CREB-binding protein-specific inhibitor curcumin inhibited acetyltransferase activity in HeLa cancer cells when applied at different concentrations [18]. Inhibiting p53 acetylation by histones and p300 leads to apoptosis. In LNCaP, prostate cancer cells treated with curcumin upregulates both phosphorylations at serine and acetylation of p53. The same natural compound induces acetylation of histone H3 and H4 at the same concentration applied for 4 h [123], suggesting that curcumin regulates apoptosis through global regulation of genes related to cell survival and/or apoptosis.

In vivo and ex vivo models of acute myeloid leukemia (AML), curcumin downregulated the expression of DNMT1. DNMT1, p65, and Sp1 become less active for binding to the promoter region of DNMT1 with curcumin. Furthermore, curcumin restored p15INK4b expression by hypomethylating its promoter, resulting in cell cycle arrest in the G1 phase and apoptosis. Curcumin suppressed tumor growth in mice implanted with the MV4-11 cell line of AML [124]. In a TRAMP mouse model of prostate cancer, curcumin inhibited tumor growth by reverting methylation of the Nrf2 promoter. In addition, curcumin inhibited JNK signaling and repressed the H3K4me3 epigenetic mark in LNCaP cells [99]. Curcumin and JQ-1 together suppress prostate cancer development. HT29 colon cancer cells were treated with curcumin and the colony formation and methylation of the DLEC1 promoter were inhibited. Curcumin induced specific changes in DNA methylation of a subset of genes involved in cell viability and proliferation in colorectal cancer cells as opposed to the global hypomethylation induced by 5-aza-CdR [125].

7.4. Epigenetic Modulation of Resveratrol in Cancer

Researchers are studying resveratrol (RVT) as a possible treatment for cancer, diabetes, cardiovascular diseases, neurodegenerative diseases, and metabolic diseases [126–129]. With a focus on epigenetic mechanisms, RVT has biological activities. SIRT1 is downregulated and NF-κB is upregulated in colon cancer (CC), but RVT reverses it [130]. Colon cell lines overexpressing SIRT1 showed antiproliferative effects [131]. By modulating cell cycle-regulating genes, enhancing apoptosis via p53 upregulation, and inhibiting anti-apoptotic genes, RVT inhibited colorectal cancer (CRC) cell proliferation, invasion, and metastasis [132]. In CRC cell lines, NF-κB was down-regulated after RVT. RVT inhibits nuclear translocation of NF-κB when SIRT1 mRNA levels are suppressed, suggesting RVT is SIRT1-dependent. RVT also induced premature senescence in human dermal fibroblasts, which is associated with DNA damage [133]. In vitro and in vivo, RVT has been shown to inhibit tumor growth by affecting the HDAC pathway [134–136]. RVT also downregulates MTA1 by acetylating p53 in PCa cells [114]. PTEN, a tumor suppressor, is deleted on chromosome 10 in prostate cancer or inactivated by MTA1/HDAC inhibitors. By abrogating MTA1/HDACs’ negative epigenetic effect, RVT may stimulate PTEN reactivation [137]. Downregulation of MTA1 by RVT triggers apoptosis in prostate cancer cells (PCa) by activating pro-apoptotic genes Bax and p21.

RVT induced apoptosis in Hodgkin lymphoma cells by inhibiting SIRT1 and hyperacetylation of p53/FOXO3a [138]. Acyl-p53 and acetyl-FOXO3a levels were increased after RVT treatment, indicating that deacetylase inhibition is a critical step in the apoptosis of lymphoma cells [139]. Hepatoma cell lines treated with RVT showed dose-dependent antiproliferative effects [140]. Another study found the effects of RVT on growth and apoptosis in osteoblastoma cells. Compared with normal osteoblasts, osteosarcoma cells overexpressed the SIRT1 protein after RVT [31].

7.5. Epigenetic Modulation of EGCG in Cancer

Worldwide, green tea is widely consumed and believed to prevent cancer. Green tea contains catechins, a type of polyphenol. Most abundant and most biologically active is epigallocatechin-gallate (EGCG). The anticancer properties of EGCG have been extensively studied [141–143]. DNA methylation is inhibited by GTPs, which leads to
hypomethylation and activation of epigenetically silenced genes. To evaluate the effect of GTPs on DNA methylation, several in vitro experiments have been carried out. A review article summarizes the effect of EGCG on DNA methylation in cell culture. There could be several reasons for the discrepancy between their findings and previous studies, including different methods of analysis, possible gene specificity or cell line specificity of EGCG, or an ineffective treatment method. According to Strassmann et al. [144], in some in vitro cell culture conditions, cellular effects caused by EGCG might be attributed to the oxidative stress caused by it. In an alkaline environment, EGCG undergoes autooxidation, forming homo- and heterodimers of EGCG and EGC, resulting in the formation of H2O2. There is no doubt that auto-oxidation occurs in cell culture and during digestion, but how much it happens depends on the medium [144]. H2O2 formation, however, was mostly ignored in cell culture experiments. As a result of GTP treatment, silenced genes are re-expressed in in vitro cell culture. DNA methylation will be changed by EGCG concentrations of 20–50 mol/L for 3–6 days. The level is far higher than what mice or humans can physiologically handle [145]. Therefore, GT interventions might not be suitable for therapeutic purposes, but they might affect DNA methylation long term.

Sulforaphane has been shown to enhance EGCG’s DNMT1-inhibitory effect, and at the same time, enhance hTERT inhibition [146]. GT treatment has anticarcinogenic properties in vitro, but EGCG’s limited chemical stability at alkaline pH under normal physiological conditions makes it difficult to translate to the clinic. EGCG and trichostatin A boost ER-α expression in ER-α-negative breast cancer cells [147]. Synthetic analogs have been developed to increase the chemical stability of EGCG, showing stronger anticancer activity and more stability and efficacy [148–150]. EGCG inhibits hTERT expression by inducing DNA hypomethylation and promoter deacetylation via DNMTs and histone acetylases, respectively [151]. EGCG and pEGCG inhibited the proliferation of human ER-positive in MCF-7 and ER-negative in MDA-MB-231 breast cancer cells, but not normal cells [152]. In addition, EGCG treatment inhibited the gene and protein expression of DNMT1, DNMT3a, and DNMT3b [153]. Treatment with EGCG led to a significant boost in RECK mRNA expression in oral carcinoma cells (SCC9 and HSC3) [154].

7.6. Epigenetic Modulation of Quercetin in Cancer

Flavonoids such as quercetin are found in apples, onions, red wine, and green tea [155,156]. Quercetin causes pro-apoptotic effects in tumor cells without affecting normal ones [157]. DNMT, HDAC, and HMT are all reduced by quercetin in a dose-dependent manner in human cervical cancer cells [158]. Quercetin seems to have an anticancer effect through epigenetic pathways [159,160]. A study used human acute myeloid leukemia cells and HL60 and U937 cell lines. Quercetin treatment eliminated DNMT1 and DNMT3a effects [161]. Quercetin treatment increases apoptosis by DNA demethylation, HDAC inhibition, and H3Ac and H4Ac enrichment in promoter regions of apoptotic genes. Researchers found quercetin and sodium butyrate downregulated DNMT1, HDAC1, and cyclin D1 [162]. HDAC-NF-κB signaling is inhibited by this combination. Quercetin and curcumin combined treatment resulted in the sensitization of resistant prostate cancer cells to anti-androgen therapy [163]. However, quercetin inhibits HDAC1 and DNMT1 in hamster buccal pouch carcinoma [164], which has a pivotal role in cell survival, and invasiveness, angiogenesis, and cell proliferation. In addition, another researcher found quercetin blocks bound transactivators CREB2, C-Jun, C/EBP*, and NF-κB and the recruitment of the coactivator p300 (Figure 3) [142–160]. Quercetin inhibited the acetylation of NF-κB by p300 HAT. Another study found that quercetin inhibited colorectal cancer growth by activating p16INK4a induced by promoter demethylation [161]. Quercetin promotes cell death in leukemic HL-60 cells by activating FasL and H3 acetylation. Curcumin and quercetin together restored AR protein levels in androgen-receptor negative prostate cancer cells. DNMT decreased, resulting in global hypomethylation and mitochondrial depolarization, which induced apoptosis.
8. Conclusions

Many kinds of cancer are triggered by epigenetic changes. Thus, epigenetic therapy is a valid strategy to stop cancer from spreading. There are a significant number of active molecules in natural compounds, including some that modulate gene expression epigenetically, which deserves more study. DNA aberrations that cause neoplastic transformation can be reversed by many dietary polyphenols. Oncogenes and tumor suppressor genes are epigenetic targets of polyphenol action, which are indirectly controlled by epigenetic enzymes such as DNMTs, HATs, and HDACs. Several polyphenols, including kaempferol, gallic acid, curcumin, resveratrol, EGCG, and quercetin, have been found to downregulate HDAC expression, mostly HDAC 1 and HDAC 3. Polyphenols regulate epigenetic machineries, which may prevent normal cells from turning into tumors. In this review, the majority of studies on polyphenols and epigenetic modifications used cancer cell culture models. The epigenetic modifying effect of these polyphenols on cancer needs further study in vivo.

Author Contributions: Conceptualization, P.R. and E.A.A.; writing—original draft preparation, P.R., K.R., R.B.A., and V.V.; writing—review and editing, P.R., R.B.A., and S.A.A.; supervision, P.R. and E.A.A. All authors have read and agreed to the published version of the manuscript.

Funding: The author acknowledged the Deanship of Scientific Research, Vice Presidency at King Faisal University Saudi Arabia for financial support under the annual funding track (Grant 1028).
Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: Deanship of Scientific Research at King Faisal University, Saudi Arabia.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Van de Gucht, M.B.; Janssen, C.R. Epigenetics and its implications for ecotoxicology. Ecotoxicology 2011, 20, 607–624. [CrossRef]
2. Foolchand, A. Methyl Picolinic Acid Plays a Role in Epigenetic Modifications in Human HepG2 Liver Cells. Ph.D. Dissertation, University of Kwazulu-Natal, Berea, South Africa, 2019.
3. Jablonka, E.; Lamb, M.J. The expanded evolutionary synthesis—A response to Godfrey-Smith, Haig, and West-Eberhard. Biol. Philos. 2007, 22, 453–472. [CrossRef]
4. Deans, C.; Maggert, K.A. What do you mean, “epigenetic”? Genetics 2015, 199, 887–896. [CrossRef]
5. Maccani, M.A.; Marsit, C.J. Epigenetics in the placenta. Am. J. Reprod. Immunol. 2009, 62, 78–89. [CrossRef]
6. Wiesel-Motiuk, N.; Assaraf, Y.G. The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology. Drug Resist. Updat. 2020, 53, 100729. [CrossRef]
7. Tost, J. DNA methylation: An introduction to the biology and the disease-associated changes of a promising biomarker. Mol. Biotechnol. 2010, 44, 71–81. [CrossRef] [PubMed]
8. Kim, S.; Kaang, B.-K. Epigenetic regulation and chromatin remodeling in learning and memory. Exp. Mol. Med. 2017, 49, e281. [CrossRef] [PubMed]
9. Pastar, I.; Marjanovic, J.; Stone, R.C.; Chen, V.; Burgess, J.L.; Mervis, J.S.; Tomic-Canic, M. Epigenetic regulation of cellular functions in wound healing. Exp. Dermatol. 2021, 30, 1073–1089. [CrossRef]
10. Kumar, H.; Chaudhary, A.; Singh, A.; Sukhija, N.; Panwar, A.; Saravanan, K.; Bhaladhe, A.; Kaisa, K.; Panigrahi, M. A review on epigenetics: Manifestations, modifications, methods & challenges. J. Entomol. Zool. Stud. 2020, 8, 1–6.
11. Andersen, G.B.; Tost, J. A summary of the biological processes, disease-associated changes, and clinical applications of DNA methylation. DNA Methylation Protoc. 2018, 1708, 3–30.
12. Castilho, R.M.; Scurarize, C.H.; Almeida, L.O. Epigenetic modifications and head and neck cancer: Implications for tumor progression and resistance to therapy. Int. J. Mol. Sci. 2017, 18, 1506. [CrossRef]
13. Biswas, S.; Rao, C.M. Epigenetics in cancer: Fundamentals and beyond. Pharmacol. Ther. 2017, 173, 118–134. [CrossRef] [PubMed]
14. Johnson, C.; Warmoes, M.O.; Shen, X.; Locasale, J.W. Epigenetics and cancer metabolism. Cancer Lett. 2015, 356, 309–314. [CrossRef] [PubMed]
15. Kinnaird, A.; Zhao, S.; Wellen, K.E.; Michelakis, E.D. Metabolic control of epigenetics in cancer. Nat. Rev. Cancer 2016, 16, 694–707. [CrossRef] [PubMed]
16. Shankar, E.; Kanwal, R.; Candamo, M.; Gupta, S. Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges. In Proceedings of the Seminars in Cancer Biology; Elsevier: Amsterdam, The Netherlands, 2016; pp. 82–99.
17. Sapienza, C.; Issa, J.-P. Diet, nutrition, and cancer epigenetics. Annu. Rev. Nutr. 2016, 36, 665–681. [CrossRef]
18. Carlos-Reyes, Á.; López-González, J.S.; Meneses-Flores, M.; Gallardo-Rincón, D.; Ruiz-García, E.; Marchat, L.A.; Astudillo-De La Vega, H.; Hernández de la Cruz, O.N.; López-Camarillo, C. Dietary compounds as epigenetic modulating agents in cancer. Front. Genet. 2019, 10, 79. [CrossRef]
19. Lévesque, S.; Pol, J.G.; Ferrere, G.; Galluzzi, L.; Zitvogel, L.; Kroemer, G. Trial watch: Dietary interventions for cancer therapy. Oncoimmunology 2019, 8, e1591878. [CrossRef]
20. Salisbury, D.; Bronas, U. Reactive Oxygen and Nitrogen Species: Impact on Endothelial Dysfunction. Nurs. Res. 2015, 64, 53–66. [CrossRef] [PubMed]
21. Zhang, H.; Tsao, R. Dietary Polyphenols, Oxidative Stress and Antioxidant and Anti-inflammatory Effects. Curr. Opin. Food Sci. 2016, 8, 33–42. [CrossRef]
22. Reis, J.F.; Monteiro, V.V.S.; De Souza Gomes, R.; Do Carmo, M.M.; Da Costa, G.V.; Ribera, P.C.; Monteiro, M.C. Action Mechanism and Cardiovascular Effect of Anthocyanins: An Systematic Review of Animal and Human Studies. J. Transl. Med. 2016, 14, 315. [CrossRef]
23. Rudrapal, M.; Khairnar, S.J.; Khan, J.; Dukhyil, A.B.; Ansari, M.A.; Alomary, M.N.; Alshahrmi, F.M.; Palai, S.; Deb, P.K.; Devi, R. Dietary Polyphenols and Their Role in Oxidative Stress-Induced Human Diseases. Insights into Protective Effects, Antioxidant Potentials and Mechanism (s) of Action. Front. Pharmacol. 2022, 13, 806470. [CrossRef] [PubMed]
24. Federico, A.; Morgillo, F.; Tuccillo, C.; Ciardiello, F.; Loguercio, C. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer 2007, 121, 2381–2386. [CrossRef]
25. Khansari, N.; Shakiba, Y.; Mahmoudi, M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat. Inflamm. Allergy Drug Discov. 2009, 3, 73–80. [CrossRef]
26. Azqueta, A.; Collins, A. Polyphenols and DNA Damage: A Mixed Blessing. Nutrients 2016, 8, 785. [CrossRef] [PubMed]
27. Papiez, M.A. The influence of curcumin and (-)-epicatechin on the genotoxicity and myelosuppression induced by etoposide in bone marrow cells of male rats. Drug Chem. Toxicol. 2013, 36, 93–101. [CrossRef]
28. García-Lafuente, A.; Guillamón, E.; Villares, A.; Rostagno, M.A.; Martínez, J.A. Flavonoids as anti-inflammatory agents: Implications in cancer and cardiovascular disease. Inflamm. Res. 2009, 58, 537–552. [CrossRef] [PubMed]
29. Hazel, T.G.; Nathans, D.; Lau, L.F. A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. Proc. Natl. Acad. Sci. USA 1988, 85, 8444–8448. [CrossRef] [PubMed]
30. Kamdar, S.; Vinodhkumar, R.; Anandakumar, P.; Jagan, S.; Ramakrishnan, G.; Devaki, T. The effects of quercetin on antioxidant status and tumor markers in the lung and serum of mice treated with benzo (a) pyrene. Biol. Pharm. Bull. 2007, 30, 2268–2273. [CrossRef]
31. Shankar, S.; Ganapathy, S.; Hingorani, S.R.; Srivastava, R.K. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front. Biosci. J. Virtual Libr. 2008, 13, 440–452. [CrossRef]
32. Sharma, V.; Rao, L.J.M. A thought on the biological activities of black tea. Crit. Rev. Food Sci. Nutr. 2009, 49, 379–404. [CrossRef]
33. Kim, S.Y.; Park, C.; Jang, H.-J.; Kim, B.-O.; Bae, H.-W.; Chung, I.-Y.; Kim, E.S.; Cho, Y.-H. Antibacterial strategies inspired by the oxidative stress and response networks. J. Microbiol. 2019, 57, 203–212. [CrossRef] [PubMed]
34. Wang, S.; Moustaid-Moussa, N.; Chen, L.; Mo, H.; Shastri, A.; Su, R.; Bapat, P.; Kwun, I.; Shen, C.-L. Novel insights of dietary polyphenols and obesity. J. Nutr. Biochem. 2014, 25, 1–18. [CrossRef] [PubMed]
35. Cory, H.; Passarelli, S.; Szeto, J.; Tamez, M.; Mattei, J. The role of polyphenols in human health and food systems: A mini-review. Front. Nutr. 2018, 5, 87. [CrossRef]
36. Holásková, I.; Elliott, M.; Hanson, M.L.; Schafer, R.; Barnett, J.B. Prenatal cadmium exposure produces persistent changes to thymus and spleen phenotypic repertoire as well as the acquired immune response. Toxicol. Appl. Pharmacol. 2012, 265, 181–189. [CrossRef]
37. Lewinska, A.; Wnuk, M.; Grabowska, W.; Zabek, T.; Semik, E.; Sikora, E.; Bielak-Zmijewska, A. Curcumin induces oxidation-dependent cell cycle arrest mediated by sirt7 inhibition of dna transcription in human aortic smooth muscle cells. Toxicol. Lett. 2015, 233, 227–238. [CrossRef]
38. Majidinia, M.; Bishaye, A.; Yousefi, B. Polyphenols: Major regulators of key components of DNA damage response in cancer. DNA Repair 2019, 82, 102679. [CrossRef]
39. Rajendra, P.; Alzahrani, A.M.; Renganarajan, T.; Kaushik, R.; Arulsevan, P.; Umanaheswari, A. Polyphenols and Cancer. In Frontiers in Anti-Cancer Drug Discovery; Bentham Science Publishers: Singapore, 2019; Volume 10, p. 62.
40. Locke, W.J.; Guanzon, D.; Ma, C.; Liew, Y.J.; Duesing, K.R.; Fung, K.Y.; Ross, J.P. DNA methylation cancer biomarkers: Translation to the clinic. Front. Genet. 2019, 10, 1150. [CrossRef]
41. Koch, A.; Joosten, S.C.; Feng, Z.; de Ruijter, T.C.; Draht, M.X.; Melotte, V.; Smits, K.M.; Veeck, J.; Herman, J.G.; Van Neste, L. Analysis of DNA methylation in cancer: Location revisited. Nat. Rev. Clin. Oncol. 2018, 15, 459–466. [CrossRef]
42. Paska, A.V.; Hudler, P. Aberrant methylation patterns in cancer: A clinical view. Biochem. Med. 2015, 25, 161–176. [CrossRef]
43. Udali, S.; Guarini, P.; Ruzzene, A.; Ferrari, A.; Guglielmi, A.; Lotto, V.; Tononi, P.; Pattini, P.; Moruzzi, S.; Campagnaro, T. DNA methylation and gene expression profiles show novel regulatory pathways in hepatocellular carcinoma. Clin. Epigenetics 2015, 7, 1–13. [CrossRef]
44. Xu, R.-h.; Wei, W.; Krawczyk, M.; Wang, W.; Luo, H.; Flagg, K.; Yi, S.; Shi, W.; Qian, Q.; Li, K. Circulating tumour DNA methylation markers for diagnosis and prognostic of hepatocellular carcinoma. Nat. Mater. 2017, 16, 1155–1161. [CrossRef] [PubMed]
45. Zhang, Y.; Petropoulos, S.; Liu, J.; Cheishvili, D.; Zhou, R.; Dymov, S.; Li, K.; Li, N.; Szyf, M. The signature of liver cancer in immune cells DNA methylation. Clin. Epigenetics 2018, 10, 1–17. [CrossRef]
46. Hao, X.; Luo, H.; Krawczyk, M.; Wei, W.; Wang, W.; Wang, J.; Flagg, K.; Hou, J.; Zhang, H.; Yi, S. DNA methylation markers for diagnosis and prognosis of common cancers. Proc. Natl. Acad. Sci. USA 2017, 114, 7414–7419. [CrossRef] [PubMed]
47. Villanueva, A.; Portela, A.; Sayols, S.; Battistoni, C.; Hoshida, Y.; Méndez-González, J.; Imbeaud, S.; Letouzé, E.; Hernandez-Gea, V.; Cornella, H. DNA methylation-based prognosis and epipriders in hepatocellular carcinoma. Hepatology 2015, 61, 1945–1956. [CrossRef] [PubMed]
48. Li, L.; Li, W. Epithelial–mesenchymal transition in human cancer: Comprehensive reprogramming of metabolism, epigenetics, and differentiation. Pharmacol. Ther. 2015, 150, 33–46. [CrossRef] [PubMed]
49. Feinberg, A.P.; Koldobskiy, M.A.; Göndör, A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet. 2016, 17, 284–299. [CrossRef]
50. Qian, Z.; Shen, Q.; Yang, X.; Qiu, Y.; Zhang, W. The role of extracellular vesicles: An epigenetic view of the cancer microenvironment. Biomed Res. Int. 2015, 2015, 649161. [CrossRef] [PubMed]
51. Ilyas, M. Next-generation sequencing in diagnostic pathology. Pathobiology 2017, 84, 292–305. [CrossRef]
52. Kurumizaka, H.; Kijirai, T.; Takizawa, Y. Contributions of histone variants in nucleosome structure and function. J. Mol. Biol. 2021, 433, 166678. [CrossRef]
53. Bilokapic, S.; Strauss, M.; Halic, M. Histone octamer rearranges to adapt to DNA unwrapping. Nat. Struct. Mol. Biol. 2018, 25, 101–108. [CrossRef]
54. Zou, T.; Hashiya, F.; Wei, Y.; Yu, Z.; Pandian, G.N.; Sugiyama, H. Direct observation of H3–H4 octasome by high-speed AFM. Chem. A Eur. J. 2018, 24, 15998–16002. [CrossRef] [PubMed]
81. Williamson, G. The role of polyphenols in modern nutrition. Nutr. Bull. 2017, 42, 226–235. [CrossRef] [PubMed]
82. Tsao, R. Chemistry and biochemistry of dietary polyphenols. Nutrients 2010, 2, 1231–1246. [CrossRef] [PubMed]
83. Rana, A.; Samtiya, M.; Dhewa, T.; Mishra, V.; Aluko, R.E. Health benefits of polyphenols: A concise review. J. Food Biochem. 2022, 13, e14264. [CrossRef] [PubMed]
84. Del Rio, D.; Costa, L.G.; Lean, M.E.; Crozier, A. Polyphenols and health: What compounds are involved? Nutr. Metab. Cardiovasc. Dis. 2010, 20, 1–6. [CrossRef] [PubMed]
85. Rajendran, P.; Rengarajan, T.; Nandakumar, N.; Divya, H.; Nishigaki, I. Mangiferin in cancer chemoprevention and treatment: Pharmacokinetics and molecular targets. J. Transl. Signal Transduct. Res. 2015, 35, 76–84. [CrossRef]
86. Rajendran, P.; Rengarajan, T.; Nishigaki, I.; Ekambaram, G.; Sakhtheesaran, D. Potent chemopreventive effect of mangiferin on lung carcinogenesis in experimental Swiss albino mice. J. Cancer Res. Ther. 2014, 10, 1033–1039. [CrossRef] [PubMed]
87. Dretcanu, G.; Ijuhas, C.I.; Diaconesea, Z. The Involvement of Natural Polyphenols in the Chemoprevention of Cervical Cancer. Int. J. Mol. Sci. 2021, 22, 8812. [CrossRef] [PubMed]
88. Shah, D.; Gandhi, M.; Kumar, A.; Cruz-Martins, N.; Sharma, R.; Nair, S. Current insights into epigenetics, noncoding RNA interacomics and clinical pharmacokinetics of dietary polyphenols in cancer chemoprevention. Crit. Rev. Food Sci. Nutr. 2021, 1–37. [CrossRef] [PubMed]
89. Rajendran, P.; Rengarajan, T.; Nandakumar, N.; Palaniswami, R.; Nishigaki, Y.; Nishigaki, I. Kaempferol, a potential cytostatic and cure for inflammatory disorders. Eur. J. Med. Chem. 2014, 86, 103–112. [CrossRef] [PubMed]
90. Amjad, E.; Sokouti, B.; Asnaashari, S. A systematic review of anti-cancer roles and mechanisms of kaempferol as a natural compound. Cancer Cell Int. 2022, 22, 260. [CrossRef] [PubMed]
91. Mohan Shankar, G.; Swetha, M.; Keerthana, C.K.; Raygina, T.P.; Anto, R.J. Cancer Chemoprevention: A Strategic Approach Using Phytochemicals. Front. Pharmacol. 2021, 12, 809308. [CrossRef]
92. Sharma, N.; Biswas, S.; Al-Dayan, N.; Alhegali, A.S.; Sarwat, M. Antioxidant Role of Kaempferol in Prevention of Hepatocellular Carcinoma. Antioxidants 2021, 10, 1419. [CrossRef]
93. Qiu, W.; Lin, J.; Zhu, Y.; Zhang, J.; Zeng, L.; Su, M.; Tian, Y. Kaempferol Modulates DNA Methylation and Downregulates DNMT3B in Bladder Cancer. Cell. Physiol. Biochem. 2017, 41, 1325–1335. [CrossRef]
94. Lu, L.; Wang, Y.; Ou, R.; Feng, Q.; Ji, L.; Zheng, H.; Guo, Y.; Qi, X.; Kong, A.N.; Liu, Z. DACT2 Epigenetic Stimulator Exerts Dual Efficacy for Colorectal Cancer Prevention and Treatment. Pharmacol. Res. 2018, 129, 318–328. [CrossRef]
95. Kim, T.H.; Ku, S.-K.; Lee, J.-C.; Bae, J.-S. Anti-inflammatory effects of kaempferol-3-O-sophoroside in human endothelial cells. Inflamm. Res. 2012, 3, 217–224. [CrossRef]
96. Kim, T.W.; Lee, S.Y.; Kim, M.; Cheon, C.; Ko, S.G. Kaempferol induces autophagic cell death via IRE1-JNK-CHOP pathway and inhibition of G9a in gastric cancer cells. Cell Death Dis. 2018, 9, 875. [CrossRef] [PubMed]
97. Imran, M.; Salehi, B.; Sharifi-Rad, J.; Aslam Gondal, T.; Saeed, F.; Imran, A.; Shahbaz, M.; Tsouh Fokou, P.V.; Umair Arshad, M.; Khan, H.; et al. Kaempferol: A Key Emphasis to Its Anticancer Potential. Molecules 2019, 24, 2277. [CrossRef] [PubMed]
98. Bhosale, P.B.; Ha, S.E.; Shirali, A.; Vetrivel, P.; Kim, H.H.; Kim, S.M.; Kim, G.S. Functions of polyphenols and its anticancer properties in biomedical research: A narrative review. Transl. Cancer Res. 2020, 9, 7619–7631. [CrossRef] [PubMed]
99. Jiang, Y.; Pei, J.; Zheng, Y.; Miao, Y.J.; Duan, B.Z.; Huang, L.F. Gallic Acid: A Potential Anti-Cancer Agent. Molecules 2018, 2021, 1–9. [CrossRef]
100. Shi, C.J.; Zheng, Y.B.; Pan, F.F.; Zhuang, P.; Fu, W.M. Gallic Acid Suppressed Tumorigenesis by an LncRNA MALAT1-Wnt/b-Catenin Axis in Hepatocellular Carcinoma. Front. Pharmacol. 2021, 12, 708967. [CrossRef]
101. Ko, E.B.; Jang, Y.G.; Ko, E.B.; Choi, K.C. Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression. Int. J. Mol. Sci. 2021, 22, 8812. [CrossRef] [PubMed]
109. Lee, W.; Lee, S.Y.; Son, Y.J.; Yun, J.M. Gallic Acid Decreases Inflammatory Cytokine Secretion Through Histone Acetyltransferase/ Histone Deacetylase Regulation in High Glucose-Induced Monocytes. J. Med. Food 2015, 18, 793–801. [CrossRef]

110. Soffaita, S.S.; Momtazi-Boroujeni, A.A.; Majeeed, M.; Derosa, G.; Maffioleti, P.; Sahebkar, A. Curcumin: A Natural Pan-HDAC Inhibitor in Cancer. Curr. Pharm. Des. 2018, 24, 123–129. [CrossRef]

111. Lee, S.J.; Krauthaiser, C.; Maduskui, V.; Fawcett, P.T.; Olson, J.M.; Rajasekaran, S.A. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo. BMC Cancer 2011, 11, 144. [CrossRef]

112. Yu, J.; Peng, Y.; Wu, L.C.; Xie, Z.; Deng, Y.; Hughes, T.; He, S.; Mo, X.; Chiu, M.; Wang, Q.E.; et al. Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. PLoS ONE 2013, 8, e59934. [CrossRef] [PubMed]

113. Teiten, M.H.; DiCato, M.; Diederich, M. Curcumin as a regulator of epigenetic events. Mol. Nutr. Food Res. 2013, 57, 1619–1629.

114. Soltani, B.; Ghaemi, N.; Sadeghizadeh, M.; Najafi, F. Curcumin confers protection to irradiated THP-1 cells while its nanoformulation sensitizes these cells via apoptosis induction. Cell Biol. Toxicol. 2016, 32, 543–561. [CrossRef]

115. Kang, S.K.; Cha, S.H.; Jeon, H.G. Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. Stem Cells Dev. 2006, 15, 165–174. [CrossRef]

116. Yuan, Z.; Syed, M.A.; Panchal, D.; Rogers, D.; Joo, M.; Sadiqot, R.T. Curcumin mediated epigenetic modulation inhibits TREM-1 expression in response to lipopolysaccharide. Int. J. Biochem. Cell Biol. 2012, 44, 2032–2043. [CrossRef] [PubMed]

117. Parashar, G.; Parashar, N.C.; Capalash, N.C. Curcumin causes promoter hypomethylation and increased expression of FANCF gene in SiHa cell line. Mol. Cell. Biochem. 2012, 365, 29–35. [CrossRef] [PubMed]

118. Shu, L.; Khor, T.O.; Lee, J.H.; Boyanapalli, S.S.; Huang, Y.; Wu, T.Y.; Saw, C.L.; Cheung, K.L.; Kong, A.N. Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. AAPS J. 2011, 13, 606–614. [CrossRef] [PubMed]

119. Zhang, C.; Su, Z.Y.; Khor, T.O.; Shu, L.; Kong, A.N. Sulforaphane enhances Nrf2 expression in prostate cancer TRAMP C1 cells through epigenetic regulation. Biochim. Biophys. Acta 2013, 85, 1398–1404. [CrossRef]

120. Kutluay, S.B.; Doroghazi, J.; Roemer, M.E.; Trizeenberg, S.J. Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. Virology 2008, 373, 239–247. [CrossRef]

121. Cui, L.; Miao, J.; Cui, L. Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: Inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob. Agents Chemother. 2007, 51, 488–494. [CrossRef]

122. Zhao, W.; Zhou, X.; Qi, G.; Guo, Y. Curcumin suppressed the prostate cancer by inhibiting JNK pathways via epigenetic regulation. J. Biochem. Mol. Toxicol. 2018, 32, e22049. [CrossRef]

123. Fernandes, G.F.S.; Silva, G.D.B.; Pavan, A.R.; Chiba, D.E.; Chin, C.M.; Dos Santos, J.L. Epigenetic Regulatory Mechanisms Induced by Resveratrol. Nutrients 2017, 9, 1201. [CrossRef]

124. Imperador, C.H.L.; Scarin, C.B.; Bosquesi, P.L.; Lopes, J.R.; Cardinalli Neto, A.; Giarolla, J.; Ferreira, E.I.; Dos Santos, J.L.; Chin, C.M. Resveratrol and Curcumin for Chagas Disease Treatment: A Systematic Review. Pharmaceuticals 2022, 15, 609. [CrossRef]

125. Albani, D.; Polito, L.; Signorini, A.; Forloni, G. Neuroprotective properties of resveratrol in different neurodegenerative disorders. BioFactors 2010, 36, 370–376. [CrossRef] [PubMed]

126. Wahab, A.; Gao, K.; Jia, C.; Zhang, F.; Tian, G.; Murtaza, G.; Chen, J. Significance of Resveratrol in Clinical Management of Chronic Diseases. Molecules 2017, 22, 1329. [CrossRef]

127. Carrizzo, A.; Forte, M.; Damato, A.; Trimario, V.; Salzano, F.; Bartolo, M.; Maciag, A.; Puca, A.A.; Vecchione, C. Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 6136–6143.

128. Aparin, S.; Giampieri, F.; Gasparri, M.; Forsberg-Hernández, T.Y.; Cianciosi, D.; Reboredo-Rodriguez, P.; Zhang, J.; Manna, P.P.; Daglia, M.; Atanasov, A.G. Dietary phytochemicals in colorectal cancer prevention and treatment: A focus on the molecular mechanisms involved. Biotechnol. Adv. 2020, 38, 107322. [CrossRef] [PubMed]

129. Vernousfadereni, E.K.; Akhtari, N.; Rezaei, S.; Rezaee, Y.; Shiranirad, S.; Mashhadi, M.; Hashemi, A.; Khankandi, H.P.; Behzad, S. Resveratrol and Colorectal Cancer: A Molecular Approach to Clinical Researches. Curr. Top. Med. Chem. 2021, 21, 2634–2646. [CrossRef] [PubMed]

130. Moreira, H.; Szyjka, A.; Grzesik, J.; Pelc, K.; Zuk, M.; Kulma, A.; Emhemmed, F.; Muller, C.D.; Gasiorowski, K.; Barg, E. Celastrol and Resveratrol Modulate SIRT Gene Expression and Exert Anticancer Activity in Colon Cancer Cells and Cancer Stem-like Cells. Cancers 2022, 14, 1372. [CrossRef] [PubMed]

131. Venturelli, S.; Berger, A.; Böcker, A.; Busch, C.; Weiland, T.; Noor, S.; Leischnner, C.; Schleicher, S.; Mayer, M.; Weiss, T.S.; et al. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS ONE 2013, 8, e73097. [CrossRef]

132. Dhar, S.; Kumar, A.; Li, K.; Tzivion, G.; Levenson, A.S. Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer. Biochim. Biophys. Acta 2015, 1853, 265–275. [CrossRef]

133. Bankole, O.; Scambi, I.; Parrella, E.; Mucilli, M.; Bonafede, R.; Turano, E.; Pizzi, M.; Mariotti, R. Beneficial and Sexually Dimorphic Response to Combined HDAC Inhibitor Valproate and AMPK/SIRT1 Pathway Activator Resveratrol in the Treatment of ALS Mice. Int. J. Mol. Sci. 2022, 23, 1047. [CrossRef]
161. Priyadarsini, R.V.; Vinothini, G.; Murugan, R.S.; Manikandan, P.; Nagini, S. The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumors. *Nutr. Cancer* **2011**, *63*, 218–226. [CrossRef]

162. Xiao, X.; Shi, D.; Liu, L.; Wang, J.; Xie, X.; Kang, T.; Deng, W. Quercetin suppresses cyclooxygenase-2 expression and angiogenesis through inactivation of P300 signaling. *PLoS ONE* **2011**, *6*, e22934. [CrossRef]

163. Gibellini, L.; Pinti, M.; Nasi, M.; Montagna, J.P.; De Biasi, S.; Roat, E.; Bertoncelli, L.; Cooper, E.L.; Cossarizza, A. Quercetin and cancer chemoprevention. *J. Evid. Based Integr. Med.* **2011**, *2011*, 591356. [CrossRef]

164. Bidian, C.; Mitrea, D.R.; Vasile, O.G.; Filip, A.; Cătoi, A.F.; Moldovan, R.; Decea, N.; Albu, A. Quercetin and curcumin effects in experimental pleural inflammation. *Med. Pharm. Rep.* **2020**, *93*, 260–266. [CrossRef]